New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
07:23 EDTPCRXPacira Pharmaceuticals upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray upgraded Pacira Pharmaceuticals to Overweight citing the FDA approval of new manufacturing capacity for Exparel. Piper believes Pacira is now able to meet the continued growth in Exparel demand and raised its price target for shares to $84 from $75.
News For PCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PCRX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use